Skip to main content
Geneuro logo

Geneuro — Investor Relations & Filings

Ticker · GEM ISIN · CH0308403085 LEI · 213800FUJCKXO9LK3444 PA Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2017-09-19 Regulatory Filings
Country CH Switzerland
Listing PA GEM

About Geneuro

https://geneuro.ch/en/

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release issued by GeNeuro and Servier announcing that they will present clinical trial results (CHANGE-MS Phase 2b) at an upcoming medical congress (MSParis2017). It provides background information on the study, the drug GNbAC1, and the companies involved. It does not contain the actual full clinical report or financial statements, but rather serves as an announcement of an upcoming presentation of data. Under the 'Menu vs Meal' rule, this is an announcement of information rather than the primary report itself, fitting the definition of a Regulatory Filing (RNS) or a general corporate announcement.
2017-09-19 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release issued by GeNeuro regarding the publication of scientific data in a medical journal and the status of a clinical trial. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement (RPA) for a formal financial filing. As it is a general corporate announcement regarding research and development activities, it falls under the fallback category of Regulatory Filings (RNS).
2017-09-11 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the publication of scientific research findings in the 'Journal of Clinical Investigation Insight' regarding the role of a specific protein in Type 1 Diabetes. It also provides updates on the company's ongoing Phase 2a clinical trial. Since this is a general corporate announcement regarding research and development progress rather than a formal financial report, dividend notice, or regulatory filing, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2017-09-11 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Earnings Release Classification · 1% confidence The document is a press release issued by GeNeuro and Servier announcing the 6-month results of a Phase 2b clinical trial (CHANGE-MS). It provides key highlights of the study findings, safety profile, and future expectations, and includes details about an upcoming conference call. It does not constitute a full financial report, audit, or regulatory filing, but rather an initial announcement of clinical trial results, which falls under the 'Earnings Release' (ER) category in the context of corporate news releases regarding performance or key operational milestones. H2 2017
2017-08-28 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Earnings Release Classification · 1% confidence The document is a press release issued by GeNeuro and Servier announcing the 6-month results of their Phase 2b clinical trial (CHANGE-MS). It provides key highlights of the trial findings, safety profile, and future expectations, while also announcing an upcoming conference call for investors. It is a standard corporate announcement of clinical trial results, which falls under the category of an Earnings Release or general regulatory announcement regarding operational progress. Given the specific focus on clinical trial results and the announcement of a conference call, it fits the 'Earnings Release' (ER) category as it serves as the primary disclosure of material operational/clinical performance. Q3 2017
2017-08-28 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Regulatory Filings Classification · 1% confidence The document is a press release detailing the status of a liquidity contract (contrat de liquidité) for GeNeuro, reporting the number of shares and cash balance held by the broker Gilbert Dupont as of June 30, 2017. This type of disclosure regarding share buyback programs or liquidity management does not fit into specific categories like 'Transaction in Own Shares' (which usually refers to the act of buying back) or 'Annual Report'. Given it is a regulatory disclosure regarding the status of a financial contract, it falls under the general regulatory filing category.
2017-07-12 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.